The role of neoadjuvant therapy in the multimodal treatment of rectal cancer – clinical outcome

Česká verzia

Authors: I. Krajčovičová ¹; E. Bolješíková ²; M. Šándorová ²
Authors place of work: I. onkologická klinika LF UK v Bratislave, Onkologický ústav sv. Alžbety, Bratislava ¹; Klinika radiačnej onkológie SZU v Bratislave, Onkologický ústav sv. Alžbety, Bratislava ²
Published in the journal: Gastroent Hepatol 2013; 67(5): 354-360
Category: Gastrointestinal Oncology: Original Article

Summary

A retrospective analysis of two pre-surgical treatment modalities in patients with stage II and III rectal neoplasms was performed from January 1998 to January 2008 at the Department of Radiation Oncology, St. Elisabeth Cancer Institute and the Slovak Medical University in Bratislava. 96 patients were treated with short-term pre-surgical radiotherapy using a total dose of 25 Gy in five fractions and subsequently treated with surgery in the five-day interval after radiotherapy. Long-term radiotherapy was applied to 55 patients with the entire doses of 50.4 Gy fractionated 1.8 to 2.0 Gy/day with or without the chemoradiotherapy based on 5-fluorouracil. In this group of patients the surgery was performed four to eight weeks after termination of the radiotherapy. Patients belonging to both investigation groups were irradiated by means of an X-ray linear accelerator 6–18 MV, the 3D conformal radiotherapy, the three convergent field technique, or by the BOX technique. The effect of both treatment modalities on the selection of surgical intervention, down-staging, pathological complete remission (pCR), frequency of local recurrences and distant metastasis, toxicity, the overall survival (OS) and disease-free survival (DFS) related to the disease stage were analysed. From the statistic perspective significantly more patients with progressing rectal cancer were treated with long-term radiotherapy as compared to short-term treatment (p = 0.00002 < 0.05). It is to be noted that all results of the present study should be considered in this context. Down-staging as well as pCR were achieved solely in patients treated with long-term radiotherapy. Concerning the LR frequency, the occurrence of distant metastasis, toxicity, OS and DFS, no statistically significant difference of long-term vs short-term radiotherapy was registered. On the other hand, in contrast to the radiotherapy alone, a statistically significant improvement in the LR, frequency of distant metastases, OS and DFS was observed in patients treated with long-term pre-surgical chemotherapy. Our results are relevant to comparable randomised studies indicating that long-term chemoradiotherapy is more beneficial for the treatment of patients with advanced rectal neoplasms. The ongoing clinical trials indicate a new alternative of pre-surgical short-term radiotherapy with concomitant chemotherapy followed by surgery in a four-week interval after the termination of radiotherapy.

Key words:
rectal neoplasms – neoadjuvant therapy – chemoradiotherapy

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
30. 8. 2013

Accepted:
23. 9. 2013

Zdroje

1. Diba C, Pleško I, Hlava P. Incidencia zhubných nádorov v Slovenskej republike 2007. Bratislava: NCZI 2012.

2. Šlampa P, Petera J. Radiační onkologie. 1. vyd. Praha: Galén 2007; 153–161.

3. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351(17): 1731–1740.

4. Gérard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24(28): 4620–4625.

5. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355(11): 1114–1123.

6. Rödel C, Arnold D,Hipp M et al. Phase I–II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2007; 70(4): 1081–1086.

7. Sebag-Montefiore D. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373(9666): 811–820.

8. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 2010; 21(9): 1743–1750.

9. Collette L, Bosset JF, den Dulk M et al. Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25(28): 4379–4386.

10. Pettersson D, Cedermark B, Holm T et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010; 97(4): 580–587.

11. Frykholm GJ, Glimelius B, Påhlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993; 36(6): 564–572.

12. Van Gijn W, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12(6): 575–582.

13. Roh MS, Colangelo LH, O’Connell MJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27(31): 5124–5130.

14. Aschele C, Cionini L, Leonardi S et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29(20): 2773–2780.

15. Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373(9666): 811–820.

16. Wiltshire KL, Ward IG, Swallow C et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys 2006; 64(3): 709–716.